Fusions - Partner-Agnostic Method Solutions in Solid Tumors
Gene fusions are the result of other genomic events, such as translocation, interstitial deletion, or chromosomal inversion. Gene fusions are known to be driver mutations in many different tumors and more recently, have emerged as therapeutic targets. While relatively rare, for example ALK rearrangements have been reported as occurring in only 3–8% of non-small lung cell cases, the emergence of targeted gene fusion therapies have made the assessment of these events in tumors extremely important. While single gene testing methods remain the standard, multigene NGS assays provide an alternative single assay approach to gene fusion detection that conserves often difficult to obtain tissue samples.
-
Most popular related searches
Details
Superior Performance, Reliable Results.
Detect known and novel fusions with Fusions, a partner-agnostic FFPE RNA-based multiplex amplicon assay.
Canexia Health’s Fusions panel is designed to target a set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
Technical Specifications
- Genes : 18
- Exons : 150
- Turnaround time : 3 to 5 days
- Sensitivity : 95%
- Specificity : 100%
- Reproducibility : 100% (same input replicates), 91.67% (including replicates with different input
Benefits
Actionable Results
A targeted set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
Rapid Turnaround Time
A simple laboratory workflow that provides rapid, reliable, results.
Comprehensive Reports
Review detailed interpretations, current treatment options, and available clinical trials.
Cost-Effective
Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.
Conserve Biopsy Tissue
Canexia Health Fusions assay allows for simultaneous hotspot testing, reducing the amount of biopsy tissue required, when compared to single-gene testing.
Accreditation
All Canexia Health assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.
Customer reviews
No reviews were found for Fusions - Partner-Agnostic Method Solutions in Solid Tumors. Be the first to review!